f***y
发帖数: 4447 | 1 http://news.ifeng.com/a/20160316/47888950_0.shtml
3月15日，复旦大学与美国HUYA（沪亚）公司在上海达成协议，复旦大学生命科学学院
教授杨青将具有自主知识产权的用于肿瘤免疫治疗的IDO抑制剂有偿许可给美国HUYA公
司。此次许可转让将至多为复旦大学和杨青教授带来6500万美元的收益。
据了解，IDO抑制剂作为具有新药靶、新机制的药物，可应用于治疗肿瘤、阿尔茨海默
病、抑郁症、白内障等多种重大疾病，社会、经济效益前景广阔。
目前，国外医药行业对于IDO抑制剂药物的市场前景颇为看好，多家国外知名药企均宣
布要加入IDO抑制剂的研发竞争。但现有的IDO抑制剂普遍抑制效力低下，尚无IDO抑制
剂药物问世。截至目前，美国New link Genetics公司与美国Incyte公司研发的相关化
合物已经进入了临床试验阶段。而杨青带头研发的新型IDO抑制剂，已经申请了国内专
利和PCT国际专利，有望成为第三个进入临床实验研究的IDO抑制剂。
据悉，协议签订后，美国HUYA公司将向复旦大学支付一定额度的首付款。若该IDO抑制
剂在在国外临床试验结果取得优效；在欧盟、美国、日本成功上市；以及年销售额达到
不同的目标后，美国HUYA公司向复旦大学支付累计不超过6500万美金的各项里程碑付款。
“可以说，6500万美金是一个比较可观的价格。” 中国医药工业研究总院副院长易八
贤向澎湃新闻记者表示，此次复旦大学与HUYA的合作给国内高校及科研机构树立了很好
的范本。
易八贤表示，相比国外更为成熟的产学研结合模式，目前国内高校和研究机构向国外输
送研究专利存在模式瓶颈，最显著的就是创新药物在课题研究阶段的估值问题得不到解
决。
“因为现在国内并没有从事此类估值的专业机构，科研机构内也没有足够的资金建立这
样的专业部门。换句话说也就是我们的研究机构市场化程度太低，这使得国内的研究在
国外的市场上常常不被认可或者估值偏低。”易八贤说。
“在过去，欧美国家在创新药研究领域一直领先国内，国内向国外输出专利的案例并不
多。”北京鼎臣医药管理咨询中心创始人史立臣告诉记者。他表示，创新药物研发是一
个投入大、风险高、周期长的过程。在过去很长一段时间内，国内创新药领域基础研究
和高端研究都较为薄弱，再加之中国新药研发出来之后审批手续较漫长，并且要通过招
标才能够进入医院，企业对于开发自主创新药的积极性不高，市场上的国产药以仿制药
为主。
随着国家科技重大专项的推出，国内的企业和研究机构开始加大了自主研发创新药物的
投入。
易八贤透露，在最近的7、8年里，国内完全拥有自主知识产权的创新药数量已经达到了
30种以上，国内的药企和科研机构向国外市场输送药物和专利的情况渐多。
目前，国内的自主知识产权新药正在进入爆发增长期。2月26日，国家卫计委副主任刘
谦在全国卫生计生科教工作会上介绍称，“十二五”期间，我国自主知识产权新药为前
50年总和的3倍；其中，139个品种获得临床批件，较“十一五”期间增加12.5倍。技术
改造了200余种大品种药物，提高了临床用药可及性。 | l*******1
发帖数: 16217 | | c****g
发帖数: 37081 | | Q**********u
发帖数: 1616 | | l*******1
发帖数: 16217 | | G*******n
发帖数: 6889 | | s**********n
发帖数: 1019 | | t******e
发帖数: 2504 | 8 孤陋寡闻，没听说过这个公司啊，在那里？在CA, NJ or MA? | p********7
发帖数: 18007 | | t******e
发帖数: 2504 | 10 好像你说对了，刚查了查，似乎是中资公司，他们说总部在上海和加州.
【在 s**********n 的大作中提到】
: 哈哈 左手卖给右手
| | | l*******1
发帖数: 16217 | 11 也许真是左手卖给右手，菌斑有人才啊
HUYA Bioscience International is the leader in enabling and accelerating the
global development of novel biopharmaceutical product opportunities
originating in China. Learn more here >
Biotechnology Company
Address: 12531 High Bluff Dr # 138, San Diego, CA 92130
Phone:(858) 798-8800 | f***y
发帖数: 4447 | 12 应该是这个
http://www.huyabio.com/
【在 t******e 的大作中提到】
: 孤陋寡闻，没听说过这个公司啊，在那里？在CA, NJ or MA?
| f***y
发帖数: 4447 | 13 https://en.wikipedia.org/wiki/Mireille_Gingras
Dr. Mireille A. Gingras (born 1971, in Montreal, Quebec) is a United States-
based Canadian-neurobiologist and entrepreneur. She founded HUYA Bioscience
International, a biotech consulting firm in 2004, and is the San Diego,
California company's President and CEO. The company has offices in Pudong,
Shanghai, China.[1][2]
In 2010 Gingras's interest in China as a source of "research-intensive,
expensive-to-develop medicines that are the stuff of patents and high profit
margins" attracted the interest of Fortune magazine.[3]
Gingras earned her Ph.D from Radboud University Nijmegen and has held
postdoctoral fellowships at Bordeaux University in France and The Scripps
Research Institute in La Jolla, California. She received her bachelor of
arts degree from Montréal's Concordia University.[4]
Also one of the founders of MIR3,[5] she is a "serial entrepreneur" as she
has described herself. [6] Gingras is at least functional in several
languages, including Mandarin, in addition to her native French.[7]
Gingras has articulated five points of advice for women who want to succeed
in biotechnology as a male-dominated profession:[8]
- 1. Commit to building and growing your career
- 2. Know your industry, and look for opportunities that would play to women
’s strengths
- 3. Move away from your comfort zone when networking
- 4. Maintain a balance between drive and patience
- 5. Speak directly and with confidence | f***y
发帖数: 4447 | | f***y
发帖数: 4447 | 15 Business model是把中国原创药物贩卖到西方国家。
http://www.nature.com/nrd/journal/v7/n10/full/nrd2695.html
Mireille Gingras, Ph.D.
CEO and President, HUYA Bioscience International, San Diego, California, USA.
Drug discovery in China
Chinese companies providing contract research services for drug discovery
and development have rapidly established themselves in recent years. There
is also increasing interest in the potential of China as a source for novel
preclinical and clinical compounds, says Mireille Gingras, CEO and President
of HUYA Bioscience International, a company that has pioneered a novel co-
development model in which such compounds are identified and licensed for
development in Western countries.
"Through our partnerships with Chinese companies and institutes, we can use
preclinical and clinical data generated in China to inform the drug
development process in the West," Gingras says. "Although additional
clinical trials must be done in the West, the Chinese data are helpful in
lowering the risk and enhancing the efficiency of drug development. In this
way, pharmaceutical companies have the benefit of access to novel validated
compounds, and Chinese organizations have the benefit of gaining access to
Western markets for their compounds."
Gingras became interested in drug discovery in China while working as a
licensing consultant searching for novel early stage compounds throughout
Europe and Asia. "Many of us were looking in the same places, and the pools
of novel compounds were depleted," she says. "I then spent time in China
meeting with heads of government research institutions, biotechnology parks,
incubators and pharmaceutical companies, and I formed HUYA because I
recognized that there were significant opportunities for drug discovery and
development. We currently have licensed two compounds from China that are in
preclinical development in the United States, thus validating our model."
The key steps in achieving this success were her education, broad
multicultural business experience and investing the necessary time to build
relationships, feels Gingras. "First, my scientific background, including a
Ph.D. and two postdocs in neurobiology, was a fundamental step," she says. "
Second, having started and grown several companies, such as MIR3, a software
company that developed advanced on-line treatment programs for
neuroaddictive diseases, I built the operational experience needed for my
current position." Her work in countries in Europe, North America and Asia
also gave her valuable experience in collaborating with individuals from
many cultures. "The third step leading to my current position as CEO was
spending most of the past 3 years in China, which has allowed me to
successfully establish and build relationships there," she concludes.
Building on these relationships to create the partnerships on which the
company is based has been challenging at times. "We're a young, flexible
company that is willing to take risks, and can work very quickly to in-
license compounds from China. However, I've had to learn to be patient when
partnerships, negotiations and agreements take longer than I expected
because of bureaucracy in larger companies," says Gingras. Nevertheless,
this aspect is also the part of her role that she finds most rewarding: "
Every day we break geographical and cultural barriers, and I am thrilled
when people understand what we are doing and want to be involved." | R*****5
发帖数: 4915 | 16 不可信，什么huya，叫忽悠公司还差不多
俺师弟在张江也开了个公司搞药物开发，其实就是玩概念骗投资人的钱。 | l******n
发帖数: 11737 | 17 milestone，投钱，做到一定程度达到一定预期投下一段
既不是直接就把钱给你东西拿走，也不是给你钱变成你的而不用花在这项研究上了
总之就是忽悠 | C*******f
发帖数: 13152 | 18
===后半句没看懂，外行问问，是不是milestone投钱的忽悠骗子多，美国一般药物转让
都啥方式？
【在 l******n 的大作中提到】
: milestone，投钱，做到一定程度达到一定预期投下一段
: 既不是直接就把钱给你东西拿走，也不是给你钱变成你的而不用花在这项研究上了
: 总之就是忽悠
| a*******m
发帖数: 14194 | 19 分期看结果给钱。
第一期还不知道能不能给100万美元，
也许他妈的连100万美元都没拿到，就废了。
记者先吹到6500万美元了。
在美帝呆过的人，都明白up to是什么意思。
每个商店都可以up to 90% off得打折，
找件没人要的东西，先把价格涨10倍， 再折一下就好了。 | R*****5
发帖数: 4915 | 20 这种宣传稿太恶劣了
有3个假设
1.若该IDO抑制剂在国外临床试验结果取得优效；
2.在欧盟、美国、日本成功上市；
3.以及年销售额达到不同的目标后，
美国HUYA公司向复旦大学支付累计不超过6500万美金的各项里程碑付款
而标题却是 “复旦将抗肿瘤药物专利4亿转售美国公司”
就像c919还没试飞，宣传稿就搞的好像要和空客，波音形成ABC三足鼎立一样。 | l******n
发帖数: 11737 | 21 就是这几千万刀除了人工设备，并不是cash-in，一般就是用来投startup，最后做成了
，startup要卖了才能cash-in，这时分钱一般出资者是大头，co-founder小头，但也发
大财了。这种多数中间就不了了之了。
【在 C*******f 的大作中提到】
:
: ===后半句没看懂，外行问问，是不是milestone投钱的忽悠骗子多，美国一般药物转让
: 都啥方式？
|
|
